Viatris Key Executives
This section highlights Viatris's key executives, including their titles and compensation details.
Find Contacts at Viatris
(Showing 0 of )
Viatris Earnings
This section highlights Viatris's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-27 | $0.61 | $0.54 |
| Read Transcript | Q3 | 2024 | 2024-11-07 | $0.68 | $0.75 |
| Read Transcript | Q2 | 2024 | 2024-08-08 | $0.68 | $0.69 |
| Read Transcript | Q1 | 2024 | 2024-05-09 | $0.67 | $0.67 |
| Read Transcript | Q4 | 2023 | 2024-02-28 | $0.67 | $0.61 |
| Read Transcript | Q3 | 2023 | 2023-11-07 | $0.74 | $0.78 |
| Read Transcript | Q2 | 2023 | 2023-08-07 | $0.71 | $0.75 |
| Read Transcript | Q1 | 2023 | 2023-05-08 | $0.69 | $0.78 |
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
$9.30
Stock Price
$11.10B
Market Cap
32.00K
Employees
Canonsburg, PA
Location
Financial Statements
Access annual & quarterly financial statements for Viatris, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $14.74B | $15.43B | $16.26B | $17.89B | $11.95B |
| Cost of Revenue | $9.12B | $8.99B | $9.77B | $12.31B | $8.15B |
| Gross Profit | $5.62B | $6.44B | $6.50B | $5.58B | $3.80B |
| Gross Profit Ratio | 38.15% | 41.70% | 39.95% | 31.20% | 31.78% |
| Research and Development Expenses | $808.70M | $910.70M | $662.20M | $681.00M | $512.60M |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.43B | $4.65B | $4.18B | $4.53B | $3.34B |
| Other Expenses | $379.20M | $111.60M | $1.20B | $1.03B | $1.49B |
| Operating Expenses | $5.61B | $5.67B | $4.84B | $5.21B | $3.86B |
| Cost and Expenses | $14.73B | $14.66B | $14.61B | $17.52B | $12.01B |
| Interest Income | $- | $- | $- | $- | $- |
| Interest Expense | $550.00M | $573.10M | $592.40M | $636.20M | $497.80M |
| Depreciation and Amortization | $- | $2.68B | $3.03B | $4.51B | $2.22B |
| EBITDA | $10.10M | $3.46B | $6.43B | $4.48B | $1.99B |
| EBITDA Ratio | 0.07% | 22.41% | 39.56% | 25.04% | 16.68% |
| Operating Income | $10.10M | $766.20M | $1.61B | $-34.00M | $-210.80M |
| Operating Income Ratio | 0.07% | 4.97% | 9.93% | -0.19% | -1.76% |
| Total Other Income Expenses Net | $-633.30M | $-563.30M | $1.20B | $-630.40M | $-510.40M |
| Income Before Tax | $-623.20M | $202.90M | $2.81B | $-664.40M | $-721.20M |
| Income Before Tax Ratio | -4.23% | 1.32% | 17.30% | -3.71% | -6.04% |
| Income Tax Expense | $11.00M | $148.20M | $734.60M | $604.70M | $-51.30M |
| Net Income | $-634.20M | $54.70M | $2.08B | $-1.27B | $-669.90M |
| Net Income Ratio | -4.30% | 0.35% | 12.78% | -7.10% | -5.61% |
| EPS | $-0.53 | $0.05 | $1.71 | $-1.05 | $-1.11 |
| EPS Diluted | $-0.53 | $0.05 | $1.71 | $-1.05 | $-1.11 |
| Weighted Average Shares Outstanding | 1.19B | 1.20B | 1.21B | 1.21B | 601.20M |
| Weighted Average Shares Outstanding Diluted | 1.19B | 1.21B | 1.22B | 1.21B | 601.20M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 27, 2020 | June 28, 2020 | March 29, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.53B | $3.74B | $3.80B | $3.66B | $3.84B | $3.94B | $3.92B | $3.73B | $3.88B | $4.08B | $4.12B | $4.19B | $4.34B | $4.54B | $4.58B | $4.43B | $3.62B | $2.97B | $2.73B | $2.62B |
| Cost of Revenue | $2.31B | $2.28B | $2.30B | $2.16B | $2.24B | $2.25B | $2.31B | $2.19B | $2.29B | $2.24B | $2.35B | $2.36B | $2.48B | $2.50B | $2.59B | $2.57B | $2.47B | $1.71B | $1.60B | $1.59B |
| Gross Profit | $1.22B | $1.46B | $1.49B | $1.50B | $1.60B | $1.69B | $1.61B | $1.54B | $1.59B | $1.84B | $1.77B | $1.83B | $1.87B | $2.04B | $1.98B | $1.86B | $1.15B | $1.26B | $1.13B | $1.03B |
| Gross Profit Ratio | 34.44% | 39.00% | 39.30% | 41.10% | 41.60% | 42.90% | 41.10% | 41.40% | 41.00% | 45.20% | 42.90% | 43.80% | 43.00% | 45.00% | 43.30% | 42.00% | 31.84% | 42.40% | 41.40% | 39.24% |
| Research and Development Expenses | $206.50M | $198.40M | $196.30M | $199.70M | $202.80M | $211.20M | $208.30M | $182.90M | $219.40M | $174.90M | $162.60M | $142.30M | $286.60M | $152.10M | $147.70M | $184.10M | $192.20M | $129.80M | $156.30M | $114.20M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.05B | $1.00B | $928.90M | $1.02B | $1.61B | $1.05B | $1.03B | $958.90M | $913.40M | $914.50M | $857.50M | $828.50M | $979.90M | $1.01B | $1.15B | $972.40M | $1.54B | $588.00M | $588.90M | $586.40M |
| Other Expenses | $141.60M | $31.50M | $607.80M | $228.20M | $873.50M | $124.90M | $167.00M | $123.30M | $658.20M | $192.70M | $197.50M | $156.10M | $677.30M | $523.30M | $737.00M | $970.40M | $306.10M | $191.00M | $251.20M | $142.60M |
| Operating Expenses | $1.39B | $1.23B | $1.73B | $1.22B | $1.81B | $1.26B | $1.24B | $1.14B | $1.79B | $1.28B | $1.22B | $1.13B | $1.94B | $1.68B | $2.03B | $2.13B | $2.03B | $908.80M | $996.40M | $843.20M |
| Cost and Expenses | $3.71B | $3.51B | $4.04B | $3.38B | $4.05B | $3.52B | $3.55B | $3.33B | $4.08B | $3.52B | $3.57B | $3.48B | $4.42B | $4.18B | $4.63B | $4.70B | $4.50B | $2.62B | $2.60B | $2.43B |
| Interest Income | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $120.20M | $145.60M | $145.80M | $138.40M | $140.90M | $141.50M | $143.70M | $147.00M | $147.10M | $153.20M | $145.90M | $146.20M | $148.20M | $151.90M | $167.10M | $169.00M | $144.40M | $117.30M | $116.20M | $119.90M |
| Depreciation and Amortization | $746.20M | $669.70M | $786.30M | $691.00M | $644.40M | $679.40M | $686.70M | $730.00M | $696.30M | $699.50M | $722.30M | $736.00M | $647.00M | $855.57M | $1.32B | $1.42B | $632.50M | $432.30M | $415.70M | $415.00M |
| EBITDA | $339.90M | $905.80M | $541.30M | $1.13B | $-64.40M | $1.26B | $1.23B | $1.26B | $1.19B | $1.45B | $1.47B | $1.60B | $693.00M | $1.74B | $1.26B | $1.15B | $84.00M | $978.40M | $841.50M | $744.00M |
| EBITDA Ratio | 9.63% | 24.23% | 30.21% | 28.23% | -1.82% | 31.03% | 29.69% | 32.17% | 30.71% | 35.61% | 35.69% | 38.17% | 29.19% | 38.36% | 43.69% | 48.34% | 2.66% | 32.92% | 30.81% | 28.41% |
| Operating Income | $-179.80M | $225.90M | $-239.90M | $203.90M | $-454.50M | $451.70M | $369.20M | $399.80M | $-201.30M | $560.10M | $548.70M | $707.40M | $-77.60M | $357.60M | $-47.80M | $-266.20M | $-881.10M | $351.40M | $134.20M | $184.70M |
| Operating Income Ratio | -5.10% | 6.04% | -6.32% | 5.57% | -11.84% | 11.46% | 9.42% | 10.72% | -5.19% | 13.73% | 13.33% | 16.88% | -1.79% | 7.88% | -1.04% | -6.01% | -24.32% | 11.82% | 4.91% | 7.05% |
| Total Other Income Expenses Net | $-346.70M | $-135.40M | $-151.90M | $700.00K | $-400.50M | $-49.50M | $-36.20M | $-77.10M | $1.67B | $-132.60M | $-159.40M | $-179.90M | $-126.30M | $-157.70M | $-171.30M | $-175.10M | $-132.40M | $-109.80M | $-114.20M | $-154.00M |
| Income Before Tax | $-526.50M | $90.50M | $-391.80M | $204.60M | $-855.00M | $402.20M | $333.00M | $322.70M | $1.47B | $427.50M | $389.30M | $527.50M | $-203.90M | $199.90M | $-219.10M | $-441.30M | $-1.01B | $241.60M | $20.00M | $30.70M |
| Income Before Tax Ratio | -14.92% | 2.42% | -10.32% | 5.58% | -22.28% | 10.20% | 8.50% | 8.65% | 37.90% | 10.48% | 9.46% | 12.58% | -4.70% | 4.41% | -4.79% | -9.96% | -27.97% | 8.13% | 0.73% | 1.17% |
| Income Tax Expense | $-10.00M | $-4.30M | $65.40M | $90.70M | $-89.40M | $70.60M | $69.00M | $98.00M | $457.70M | $73.20M | $75.40M | $128.30M | $59.90M | $111.60M | $60.10M | $596.30M | $97.70M | $55.90M | $19.40M | $9.90M |
| Net Income | $-516.50M | $94.80M | $-326.40M | $113.90M | $-765.60M | $331.60M | $264.00M | $224.70M | $1.01B | $354.30M | $313.90M | $399.20M | $-263.80M | $311.50M | $-279.20M | $-1.04B | $-915.80M | $185.70M | $39.40M | $20.80M |
| Net Income Ratio | -14.64% | 2.54% | -8.60% | 3.11% | -19.95% | 8.41% | 6.74% | 6.03% | 26.09% | 8.69% | 7.62% | 9.52% | -6.08% | 6.87% | -6.10% | -23.42% | -25.27% | 6.25% | 1.44% | 0.79% |
| EPS | $-0.43 | $0.08 | $-0.27 | $0.10 | $-0.64 | $0.28 | $0.22 | $0.19 | $0.83 | $0.29 | $0.26 | $0.33 | $-0.22 | $0.26 | $-0.23 | $-0.86 | $-1.07 | $0.36 | $0.08 | $0.04 |
| EPS Diluted | $-0.43 | $0.08 | $-0.27 | $0.09 | $-0.64 | $0.27 | $0.22 | $0.19 | $0.83 | $0.29 | $0.26 | $0.33 | $-0.22 | $0.26 | $-0.23 | $-0.86 | $-1.07 | $0.36 | $0.08 | $0.04 |
| Weighted Average Shares Outstanding | 1.19B | 1.19B | 1.19B | 1.20B | 1.20B | 1.20B | 1.20B | 1.20B | 1.22B | 1.22B | 1.21B | 1.21B | 1.20B | 1.21B | 1.21B | 1.21B | 854.40M | 516.90M | 516.90M | 520.00M |
| Weighted Average Shares Outstanding Diluted | 1.19B | 1.20B | 1.19B | 1.21B | 1.20B | 1.21B | 1.20B | 1.21B | 1.22B | 1.22B | 1.22B | 1.21B | 1.21B | 1.21B | 1.21B | 1.21B | 854.40M | 517.70M | 517.20M | 517.00M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $734.80M | $991.90M | $1.26B | $701.20M | $844.40M |
| Short Term Investments | $355.10M | $192.50M | $212.60M | $233.80M | $203.50M |
| Cash and Short Term Investments | $734.80M | $1.18B | $1.47B | $935.00M | $1.05B |
| Net Receivables | $3.22B | $4.04B | $3.24B | $4.27B | $4.84B |
| Inventory | $3.85B | $3.47B | $3.52B | $3.98B | $5.47B |
| Other Current Assets | $1.71B | $4.28B | $2.40B | $1.72B | $1.62B |
| Total Current Assets | $9.52B | $12.98B | $10.64B | $10.90B | $12.87B |
| Property Plant Equipment Net | $2.67B | $3.01B | $3.28B | $3.48B | $3.78B |
| Goodwill | $9.13B | $9.87B | $10.43B | $12.11B | $12.35B |
| Intangible Assets | $17.07B | $19.18B | $22.61B | $26.13B | $29.68B |
| Goodwill and Intangible Assets | $26.20B | $29.05B | $33.03B | $38.25B | $42.03B |
| Long Term Investments | $1.35B | $1.14B | $1.09B | $81.40M | $47.90M |
| Tax Assets | $753.00M | $692.90M | $925.90M | $1.33B | $2.15B |
| Other Non-Current Assets | $1.01B | $821.10M | $1.05B | $798.50M | $676.00M |
| Total Non-Current Assets | $31.98B | $34.71B | $39.39B | $43.94B | $48.69B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $41.50B | $47.69B | $50.02B | $54.84B | $61.55B |
| Account Payables | $1.36B | $1.38B | $1.16B | $1.66B | $1.35B |
| Short Term Debt | $87.70M | $2.02B | $1.33B | $3.44B | $3.45B |
| Tax Payables | $192.70M | $226.80M | $279.60M | $236.90M | $288.60M |
| Deferred Revenue | $- | $- | $3.10B | $4.06B | $3.58B |
| Other Current Liabilities | $4.14B | $4.15B | $3.98B | $4.55B | $5.48B |
| Total Current Liabilities | $5.78B | $7.78B | $6.75B | $9.88B | $10.56B |
| Long Term Debt | $15.98B | $16.35B | $18.20B | $19.92B | $22.66B |
| Deferred Revenue Non-Current | $- | $- | $181.40M | $200.90M | $229.50M |
| Deferred Tax Liabilities Non-Current | $1.11B | $1.74B | $2.43B | $2.81B | $3.12B |
| Other Non-Current Liabilities | $- | $1.35B | $1.58B | $1.73B | $2.25B |
| Total Non-Current Liabilities | $17.09B | $19.44B | $22.20B | $24.47B | $28.04B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $22.87B | $27.22B | $28.95B | $34.35B | $38.60B |
| Preferred Stock | $- | $- | $18.65B | $18.54B | $18.44B |
| Common Stock | $516.60M | $12.20M | $12.10M | $12.10M | $12.10M |
| Retained Earnings | $3.42B | $4.64B | $5.18B | $3.69B | $5.36B |
| Accumulated Other Comprehensive Income Loss | $-3.21B | $-2.75B | $-2.76B | $-1.74B | $-858.00M |
| Other Total Stockholders Equity | $17.91B | $18.56B | $18.65B | $18.54B | $18.44B |
| Total Stockholders Equity | $18.64B | $20.47B | $21.07B | $20.49B | $22.95B |
| Total Equity | $18.64B | $20.47B | $21.07B | $20.49B | $22.95B |
| Total Liabilities and Stockholders Equity | $41.50B | $47.69B | $50.02B | $54.84B | $61.55B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $41.50B | $47.69B | $50.02B | $54.84B | $61.55B |
| Total Investments | $1.70B | $1.33B | $306.60M | $170.60M | $132.80M |
| Total Debt | $15.99B | $18.37B | $19.27B | $23.07B | $25.84B |
| Net Debt | $15.25B | $17.38B | $18.01B | $22.37B | $24.99B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 27, 2020 | June 28, 2020 | March 29, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $734.80M | $1.88B | $917.20M | $1.01B | $991.90M | $1.31B | $629.20M | $506.60M | $1.26B | $646.70M | $664.70M | $752.40M | $701.20M | $756.60M | $673.90M | $806.90M | $844.40M | $664.50M | $323.60M | $572.40M |
| Short Term Investments | $355.10M | $169.00M | $90.80M | $164.10M | $192.50M | $254.90M | $176.80M | $173.50M | $212.60M | $74.30M | $77.20M | $84.60M | $89.20M | $87.70M | $88.10M | $85.40M | $84.90M | $80.00M | $77.60M | $69.50M |
| Cash and Short Term Investments | $734.80M | $2.05B | $1.02B | $1.18B | $1.18B | $1.56B | $806.00M | $680.10M | $1.47B | $721.00M | $741.90M | $837.00M | $790.40M | $844.30M | $762.00M | $892.30M | $929.30M | $744.50M | $401.20M | $641.90M |
| Net Receivables | $3.22B | $3.94B | $3.86B | $3.94B | $4.04B | $3.74B | $3.61B | $3.50B | $3.24B | $2.83B | $3.18B | $3.56B | $3.77B | $3.84B | $3.88B | $3.89B | $3.89B | $2.59B | $2.44B | $2.43B |
| Inventory | $3.85B | $4.08B | $3.94B | $3.82B | $3.47B | $3.67B | $3.64B | $3.66B | $3.52B | $3.38B | $3.61B | $3.80B | $3.98B | $4.08B | $4.49B | $4.94B | $5.47B | $3.02B | $2.79B | $2.64B |
| Other Current Assets | $1.71B | $1.23B | $2.85B | $3.98B | $4.28B | $2.13B | $1.82B | $1.88B | $2.40B | $3.56B | $3.64B | $3.55B | $2.36B | $2.54B | $2.62B | $2.59B | $2.58B | $980.40M | $836.90M | $889.80M |
| Total Current Assets | $9.52B | $11.31B | $11.79B | $12.92B | $12.98B | $10.93B | $9.78B | $9.63B | $10.64B | $10.49B | $11.18B | $11.74B | $10.90B | $11.31B | $11.75B | $12.32B | $12.87B | $7.33B | $6.46B | $6.60B |
| Property Plant Equipment Net | $- | $2.68B | $2.94B | $2.95B | $3.01B | $3.17B | $3.23B | $3.26B | $3.28B | $3.30B | $3.36B | $3.43B | $3.48B | $3.42B | $3.47B | $3.56B | $3.78B | $2.29B | $2.27B | $2.30B |
| Goodwill | $9.13B | $9.56B | $9.33B | $9.69B | $9.87B | $10.28B | $10.53B | $10.57B | $10.43B | $10.05B | $10.52B | $10.98B | $12.11B | $12.17B | $11.99B | $11.91B | $12.35B | $9.82B | $9.52B | $9.33B |
| Intangible Assets | $17.07B | $17.98B | $18.42B | $19.13B | $19.18B | $21.28B | $22.08B | $22.70B | $22.61B | $23.01B | $24.10B | $25.25B | $26.13B | $26.99B | $27.86B | $28.49B | $29.68B | $10.97B | $10.96B | $11.05B |
| Goodwill and Intangible Assets | $26.20B | $27.54B | $27.74B | $28.83B | $29.05B | $31.56B | $32.62B | $33.27B | $33.03B | $33.07B | $34.62B | $36.23B | $38.25B | $39.16B | $39.85B | $40.40B | $42.03B | $20.78B | $20.48B | $20.37B |
| Long Term Investments | $1.35B | $1.48B | $132.10M | $1.19B | $1.14B | $1.21B | $1.18B | $1.08B | $94.00M | $-1.10B | $-1.24B | $-1.29B | $81.40M | $11.60M | $24.20M | $33.60M | $47.90M | $57.60M | $71.40M | $81.10M |
| Tax Assets | $- | $763.10M | $685.30M | $653.20M | $692.90M | $930.40M | $966.00M | $959.10M | $925.90M | $1.10B | $1.24B | $1.29B | $1.33B | $1.45B | $2.18B | $2.00B | $2.15B | $658.10M | $749.40M | $701.30M |
| Other Non-Current Assets | $4.43B | $988.70M | $2.04B | $800.60M | $821.10M | $933.60M | $917.60M | $1.09B | $2.05B | $699.70M | $722.30M | $774.30M | $798.50M | $722.10M | $700.30M | $674.60M | $676.00M | $123.40M | $123.10M | $86.00M |
| Total Non-Current Assets | $31.98B | $33.45B | $33.54B | $34.42B | $34.71B | $37.81B | $38.92B | $39.66B | $39.39B | $38.17B | $39.95B | $41.72B | $43.94B | $44.76B | $46.23B | $46.66B | $48.69B | $23.91B | $23.69B | $23.55B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $41.50B | $44.75B | $45.33B | $47.34B | $47.69B | $48.74B | $48.70B | $49.29B | $50.02B | $48.66B | $51.13B | $53.47B | $54.84B | $56.07B | $57.98B | $58.98B | $61.55B | $31.24B | $30.16B | $30.15B |
| Account Payables | $1.36B | $1.24B | $1.50B | $1.58B | $1.38B | $1.22B | $1.31B | $1.96B | $1.16B | $897.90M | $1.18B | $1.11B | $1.66B | $1.34B | $1.80B | $2.04B | $1.63B | $1.24B | $1.09B | $1.13B |
| Short Term Debt | $95.40M | $1.45B | $2.45B | $1.98B | $2.02B | $1.39B | $1.43B | $788.20M | $1.33B | $1.34B | $1.86B | $3.34B | $3.44B | $3.68B | $3.54B | $2.38B | $3.45B | $3.25B | $3.21B | $1.50B |
| Tax Payables | $192.70M | $284.10M | $117.70M | $148.40M | $226.80M | $206.90M | $158.10M | $244.50M | $279.60M | $106.70M | $125.70M | $177.80M | $236.90M | $198.00M | $636.00M | $752.00M | $288.60M | $343.30M | $288.00M | $254.30M |
| Deferred Revenue | $-7.70M | $- | $2.19B | $3.02B | $3.08B | $3.27B | $2.82B | $2.95B | $2.09B | $2.16B | $2.29B | $2.68B | $2.99B | $2.90B | $2.41B | $2.70B | $2.59B | $1.57B | $1.38B | $1.44B |
| Other Current Liabilities | $4.14B | $4.54B | $3.64B | $4.05B | $4.15B | $4.02B | $3.62B | $3.12B | $3.98B | $4.18B | $4.52B | $5.02B | $4.55B | $4.89B | $4.16B | $4.80B | $5.19B | $2.44B | $2.38B | $2.34B |
| Total Current Liabilities | $5.78B | $7.51B | $7.71B | $7.76B | $7.78B | $6.83B | $6.52B | $6.11B | $6.75B | $6.52B | $7.68B | $9.64B | $9.88B | $10.10B | $10.13B | $9.98B | $10.56B | $7.28B | $6.97B | $5.23B |
| Long Term Debt | $14.22B | $16.17B | $14.92B | $16.23B | $16.35B | $17.24B | $17.41B | $18.24B | $18.20B | $18.90B | $19.40B | $18.95B | $19.92B | $20.07B | $21.13B | $22.32B | $22.66B | $9.26B | $9.15B | $11.36B |
| Deferred Revenue Non-Current | $- | $- | $-1.38B | $156.20M | $165.40M | $160.50M | $166.90M | $173.20M | $-2.25B | $-2.31B | $-2.43B | $-2.54B | $-2.61B | $-2.70B | $-3.28B | $-2.80B | $-2.89B | $-1.26B | $-1.38B | $-1.37B |
| Deferred Tax Liabilities Non-Current | $- | $- | $1.57B | $1.67B | $1.74B | $2.32B | $2.41B | $2.46B | $2.43B | $2.49B | $2.62B | $2.73B | $2.81B | $2.92B | $3.49B | $3.01B | $3.12B | $1.42B | $1.54B | $1.54B |
| Other Non-Current Liabilities | $8.64B | $1.28B | $1.60B | $1.67B | $1.35B | $1.49B | $1.51B | $1.55B | $1.58B | $1.57B | $1.62B | $1.69B | $1.73B | $1.84B | $2.03B | $2.25B | $2.25B | $744.00M | $742.10M | $754.90M |
| Total Non-Current Liabilities | $22.86B | $17.45B | $18.10B | $19.57B | $19.44B | $21.04B | $21.33B | $22.25B | $22.20B | $22.96B | $23.64B | $23.38B | $24.47B | $24.83B | $26.64B | $27.59B | $28.04B | $11.42B | $11.44B | $13.65B |
| Other Liabilities | $-5.77B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $22.87B | $24.96B | $25.81B | $27.33B | $27.22B | $27.88B | $27.85B | $28.36B | $28.95B | $29.48B | $31.32B | $33.02B | $34.35B | $34.93B | $36.78B | $37.56B | $38.60B | $18.70B | $18.41B | $18.88B |
| Preferred Stock | $- | $- | $- | $18.34B | $18.56B | $- | $- | $18.43B | $18.65B | $18.62B | $18.59B | $18.56B | $18.54B | $18.51B | $18.49B | $18.46B | $18.44B | $- | $- | $7.66B |
| Common Stock | $- | $12.30M | $12.30M | $12.30M | $12.20M | $12.20M | $12.20M | $12.20M | $12.10M | $12.10M | $12.10M | $12.10M | $12.10M | $12.10M | $12.10M | $12.10M | $12.10M | $6.10M | $6.10M | $6.10M |
| Retained Earnings | $- | $4.08B | $4.13B | $4.61B | $4.64B | $5.55B | $5.37B | $5.25B | $5.18B | $4.31B | $4.11B | $3.94B | $3.69B | $4.09B | $3.91B | $4.32B | $5.36B | $6.28B | $6.09B | $6.05B |
| Accumulated Other Comprehensive Income Loss | $- | $-2.69B | $-2.98B | $-2.94B | $-2.75B | $-3.21B | $-3.01B | $-2.76B | $-2.76B | $-3.76B | $-2.90B | $-2.06B | $-1.74B | $-1.47B | $-1.20B | $-1.39B | $-858.00M | $-1.42B | $-2.02B | $-2.45B |
| Other Total Stockholders Equity | $18.64B | $18.38B | $18.35B | $18.34B | $18.56B | $18.51B | $18.47B | $18.43B | $18.65B | $18.62B | $18.59B | $18.56B | $18.54B | $18.51B | $18.49B | $18.46B | $18.44B | $7.69B | $7.67B | $7.66B |
| Total Stockholders Equity | $18.64B | $19.79B | $19.52B | $20.01B | $20.47B | $20.87B | $20.84B | $20.93B | $21.07B | $19.18B | $19.81B | $20.45B | $20.49B | $21.14B | $21.21B | $21.41B | $22.95B | $12.55B | $11.75B | $11.26B |
| Total Equity | $18.64B | $19.79B | $19.52B | $20.01B | $20.47B | $20.87B | $20.84B | $20.93B | $21.07B | $19.18B | $19.81B | $20.45B | $20.49B | $21.14B | $21.21B | $21.41B | $22.95B | $12.55B | $11.75B | $11.26B |
| Total Liabilities and Stockholders Equity | $41.50B | $44.75B | $45.33B | $47.34B | $47.69B | $48.74B | $48.70B | $49.29B | $50.02B | $48.66B | $51.13B | $53.47B | $54.84B | $56.07B | $57.98B | $58.98B | $61.55B | $31.24B | $30.16B | $30.15B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $41.50B | $44.75B | $45.33B | $47.34B | $47.69B | $48.74B | $48.70B | $49.29B | $50.02B | $48.66B | $51.13B | $53.47B | $54.84B | $56.07B | $57.98B | $58.98B | $61.55B | $31.24B | $30.16B | $30.15B |
| Total Investments | $1.70B | $1.65B | $222.90M | $256.50M | $358.20M | $245.90M | $236.40M | $159.60M | $306.60M | $74.30M | $77.20M | $84.60M | $170.60M | $99.30M | $112.30M | $119.00M | $132.80M | $137.60M | $149.00M | $150.60M |
| Total Debt | $14.31B | $17.62B | $17.09B | $17.96B | $18.12B | $18.38B | $18.60B | $18.77B | $19.27B | $19.98B | $20.98B | $22.01B | $23.07B | $23.44B | $24.37B | $24.39B | $25.79B | $12.28B | $12.14B | $12.63B |
| Net Debt | $13.57B | $15.74B | $16.17B | $16.95B | $17.13B | $17.07B | $17.97B | $18.27B | $18.01B | $19.33B | $20.32B | $21.26B | $22.37B | $22.69B | $23.69B | $23.59B | $24.94B | $11.62B | $11.82B | $12.06B |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-634.20M | $54.70M | $2.08B | $-1.27B | $-669.90M |
| Depreciation and Amortization | $2.89B | $2.74B | $3.03B | $4.51B | $2.22B |
| Deferred Income Tax | $-767.60M | $-387.10M | $-25.90M | $675.70M | $-213.20M |
| Stock Based Compensation | $146.10M | $180.70M | $116.40M | $111.20M | $79.20M |
| Change in Working Capital | $- | $-711.30M | $-922.60M | $-1.80B | $-696.30M |
| Accounts Receivables | $300.10M | $78.60M | $-240.30M | $59.30M | $78.70M |
| Inventory | $-723.40M | $-613.30M | $-259.50M | $-427.60M | $-741.90M |
| Accounts Payables | $36.00M | $314.70M | $170.20M | $-70.40M | $-82.70M |
| Other Working Capital | $- | $-491.30M | $-593.00M | $-1.37B | $49.60M |
| Other Non Cash Items | $665.40M | $922.10M | $-1.32B | $797.40M | $515.90M |
| Net Cash Provided by Operating Activities | $2.30B | $2.80B | $2.95B | $3.02B | $1.23B |
| Investments in Property Plant and Equipment | $-326.00M | $-377.00M | $-443.00M | $-509.40M | $-681.20M |
| Acquisitions Net | $-350.00M | $-667.70M | $1.96B | $277.00M | $415.80M |
| Purchases of Investments | $-26.00M | $-26.30M | $-30.20M | $-30.20M | $-104.80M |
| Sales Maturities of Investments | $26.00M | $26.30M | $29.90M | $29.80M | $47.00M |
| Other Investing Activities | $2.48B | $280.60M | $1.52B | $-394.40M | $-659.10M |
| Net Cash Used for Investing Activities | $1.80B | $-764.10M | $1.52B | $-117.80M | $-301.10M |
| Debt Repayment | $-3.71B | $-1.25B | $-3.28B | $-2.10B | $-401.30M |
| Common Stock Issued | $2.50M | $3.10M | $3.30M | $- | $600.00K |
| Common Stock Repurchased | $-250.00M | $-250.00M | $- | $-17.40M | $- |
| Dividends Paid | $-574.80M | $-575.60M | $-581.60M | $-399.00M | $- |
| Other Financing Activities | $205.60M | $-229.80M | $-17.60M | $-513.90M | $-205.00M |
| Net Cash Used Provided by Financing Activities | $-4.33B | $-2.30B | $-3.88B | $-3.01B | $-605.70M |
| Effect of Forex Changes on Cash | $-30.70M | $-2.50M | $-38.90M | $-30.90M | $33.80M |
| Net Change in Cash | $-257.50M | $-268.90M | $556.30M | $-143.80M | $358.90M |
| Cash at End of Period | $736.10M | $993.60M | $1.26B | $706.20M | $850.00M |
| Cash at Beginning of Period | $993.60M | $1.26B | $706.20M | $850.00M | $491.10M |
| Operating Cash Flow | $2.30B | $2.80B | $2.95B | $3.02B | $1.23B |
| Capital Expenditure | $-326.00M | $-474.50M | $-443.00M | $-509.40M | $-681.20M |
| Free Cash Flow | $1.98B | $2.33B | $2.51B | $2.51B | $550.60M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 27, 2020 | June 28, 2020 | March 29, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-516.50M | $94.80M | $-326.40M | $113.90M | $-765.60M | $331.60M | $264.00M | $224.70M | $1.01B | $354.30M | $313.90M | $399.20M | $-263.80M | $311.50M | $-279.20M | $-1.04B | $-915.80M | $185.70M | $39.40M | $20.80M |
| Depreciation and Amortization | $746.20M | $669.70M | $786.30M | $691.00M | $644.40M | $679.40M | $686.70M | $730.00M | $696.30M | $699.50M | $722.30M | $736.00M | $647.00M | $-172.90M | $1.32B | $1.42B | $632.50M | $432.30M | $415.70M | $415.00M |
| Deferred Income Tax | $-248.90M | $-312.40M | $-154.40M | $-51.90M | $-207.20M | $-85.00M | $-68.20M | $-26.70M | $153.60M | $-21.90M | $-104.80M | $-52.80M | $-52.90M | $147.00M | $293.20M | $288.40M | $-2.80M | $-90.70M | $-75.80M | $-43.90M |
| Stock Based Compensation | $32.30M | $32.40M | $34.70M | $46.70M | $55.80M | $43.10M | $39.20M | $42.60M | $29.70M | $29.10M | $29.40M | $28.30M | $22.50M | $25.00M | $31.00M | $32.70M | $29.40M | $15.10M | $15.30M | $19.40M |
| Change in Working Capital | $154.70M | $401.40M | $-214.60M | $-186.80M | $-276.80M | $8.30M | $-411.40M | $-31.40M | $-642.60M | $-58.90M | $-364.70M | $-51.90M | $-353.20M | $-132.40M | $68.60M | $-617.80M | $-233.70M | $-274.90M | $-125.40M | $16.80M |
| Accounts Receivables | $300.50M | $-33.00M | $22.80M | $9.80M | $81.40M | $-72.00M | $-145.80M | $215.00M | $-339.20M | $241.20M | $-26.80M | $-115.50M | $-9.80M | $183.80M | $-54.90M | $-59.80M | $106.00M | $-149.90M | $49.00M | $73.60M |
| Inventory | $-35.60M | $-129.00M | $-188.40M | $-370.40M | $-127.60M | $-219.20M | $-115.40M | $-151.10M | $180.10M | $-169.50M | $-201.00M | $-69.10M | $-76.50M | $-10.10M | $-137.60M | $-203.40M | $-209.50M | $-256.60M | $-144.00M | $-131.80M |
| Accounts Payables | $45.70M | $-66.00M | $-231.60M | $287.90M | $78.40M | $43.60M | $9.30M | $183.40M | $245.60M | $-329.90M | $284.70M | $-30.20M | $38.00M | $-54.90M | $-245.40M | $191.90M | $17.00M | $134.80M | $-33.50M | $-201.00M |
| Other Working Capital | $-155.90M | $629.40M | $182.60M | $-114.10M | $-309.00M | $255.90M | $-159.50M | $-278.70M | $-483.50M | $-130.60M | $-136.90M | $132.70M | $-266.90M | $-306.10M | $261.10M | $-354.60M | $-130.20M | $131.60M | $-30.40M | $75.00M |
| Other Non Cash Items | $314.90M | $-59.40M | $253.50M | $1.70M | $1.03B | $-153.50M | $14.80M | $32.00M | $-952.00M | $-155.00M | $101.60M | $26.90M | $470.60M | $1.05B | $-578.10M | $1.05B | $523.80M | $166.80M | $34.50M | $-180.90M |
| Net Cash Provided by Operating Activities | $482.70M | $826.50M | $379.10M | $614.60M | $479.40M | $823.90M | $525.10M | $971.20M | $142.60M | $869.00M | $802.50M | $1.14B | $523.10M | $1.09B | $559.40M | $848.80M | $36.20M | $525.00M | $379.50M | $291.10M |
| Investments in Property Plant and Equipment | $-153.40M | $-76.00M | $-58.80M | $-50.80M | $-200.90M | $-91.90M | $-99.20M | $-82.50M | $-153.70M | $-103.90M | $-83.90M | $-64.50M | $-197.40M | $-121.00M | $-89.30M | $-49.50M | $-116.90M | $-38.20M | $-44.50M | $-43.40M |
| Acquisitions Net | $- | $- | $437.80M | $-350.00M | $364.70M | $300.00K | $12.40M | $-667.70M | $1.95B | $600.00K | $7.70M | $5.10M | $2.40M | $13.70M | $86.40M | $277.00M | $415.80M | $800.00K | $900.00K | $400.00K |
| Purchases of Investments | $-4.30M | $-8.40M | $-5.60M | $-7.70M | $-5.40M | $-4.30M | $-7.60M | $-9.00M | $-6.90M | $-10.10M | $-4.60M | $-8.60M | $-3.90M | $-6.80M | $-7.20M | $-12.30M | $-8.70M | $-5.90M | $-36.60M | $-53.60M |
| Sales Maturities of Investments | $4.30M | $8.40M | $5.60M | $7.70M | $5.40M | $4.30M | $7.60M | $9.00M | $6.90M | $10.20M | $4.30M | $8.50M | $3.80M | $6.80M | $6.90M | $12.30M | $8.40M | $5.50M | $15.00M | $18.10M |
| Other Investing Activities | $-15.30M | $1.82B | $-3.20M | $195.70M | $115.80M | $-43.60M | $-86.80M | $-81.80M | $1.94B | $-11.10M | $1.80M | $-2.40M | $-21.70M | $2.80M | $72.50M | $8.80M | $-321.20M | $-20.50M | $-30.00M | $-102.20M |
| Net Cash Used for Investing Activities | $-168.70M | $1.75B | $375.80M | $-154.30M | $115.80M | $-43.60M | $-86.80M | $-749.50M | $1.78B | $-115.00M | $-82.10M | $-66.90M | $-219.10M | $-118.20M | $-16.80M | $236.30M | $-22.30M | $-58.70M | $-74.50M | $-145.60M |
| Debt Repayment | $-1.38B | $-1.54B | $-801.70M | $- | $-500.20M | $-22.90M | $-181.50M | $-545.50M | $-1.20B | $-614.40M | $-627.20M | $-838.30M | $-215.10M | $-733.60M | $-87.20M | $-1.06B | $154.10M | $100.00K | $-555.90M | $100.00K |
| Common Stock Issued | $600.00K | $600.00K | $700.00K | $600.00K | $600.00K | $800.00K | $800.00K | $900.00K | $800.00K | $1.80M | $700.00K | $- | $- | $- | $7.80M | $-7.80M | $- | $- | $- | $600.00K |
| Common Stock Repurchased | $- | $- | $- | $-250.00M | $- | $- | $- | $-250.00M | $- | $- | $- | $-9.90M | $-300.00K | $-3.60M | $- | $-7.80M | $-800.00K | $- | $-2.10M | $-5.00M |
| Dividends Paid | $-143.30M | $-143.20M | $-145.50M | $-142.80M | $-144.00M | $-143.90M | $-143.90M | $-143.80M | $-145.50M | $-145.50M | $-145.50M | $-145.10M | $-133.00M | $-133.00M | $-133.00M | $- | $- | $- | $- | $- |
| Other Financing Activities | $98.30M | $42.10M | $98.60M | $-33.40M | $-282.50M | $68.40M | $21.10M | $-36.30M | $15.30M | $-600.00K | $-7.60M | $-15.70M | $-800.00K | $-10.90M | $-473.10M | $-35.90M | $-5.00M | $-145.80M | $-28.40M | $-24.90M |
| Net Cash Used Provided by Financing Activities | $-1.42B | $-1.64B | $-847.90M | $-425.60M | $-926.10M | $-97.60M | $-303.50M | $-974.70M | $-1.33B | $-758.70M | $-779.60M | $-1.01B | $-349.20M | $-877.50M | $-685.50M | $-1.10B | $149.10M | $-145.70M | $-584.30M | $-24.80M |
| Effect of Forex Changes on Cash | $-37.80M | $23.90M | $-4.40M | $-12.40M | $12.70M | $-2.30M | $-14.10M | $1.20M | $15.60M | $-14.30M | $-28.80M | $-11.40M | $-10.30M | $-7.30M | $8.90M | $-22.20M | $19.80M | $21.80M | $16.10M | $-23.90M |
| Net Change in Cash | $-1.14B | $961.60M | $-97.40M | $22.30M | $-318.20M | $680.40M | $120.70M | $-751.80M | $612.10M | $-19.00M | $-88.00M | $51.20M | $-55.50M | $82.60M | $-134.00M | $-36.90M | $182.90M | $342.40M | $-263.20M | $96.80M |
| Cash at End of Period | $736.10M | $1.88B | $918.50M | $1.02B | $993.60M | $1.31B | $631.40M | $510.70M | $1.26B | $650.40M | $669.40M | $757.40M | $706.20M | $761.70M | $679.10M | $813.10M | $850.00M | $667.10M | $324.70M | $587.90M |
| Cash at Beginning of Period | $1.88B | $918.50M | $1.02B | $993.60M | $1.31B | $631.40M | $510.70M | $1.26B | $650.40M | $669.40M | $757.40M | $706.20M | $761.70M | $679.10M | $813.10M | $850.00M | $667.10M | $324.70M | $587.90M | $491.10M |
| Operating Cash Flow | $482.70M | $826.50M | $379.10M | $614.60M | $479.40M | $823.90M | $525.10M | $971.20M | $142.60M | $869.00M | $802.50M | $1.14B | $523.10M | $1.09B | $559.40M | $848.80M | $36.20M | $525.00M | $379.50M | $291.10M |
| Capital Expenditure | $-153.40M | $-76.00M | $-58.80M | $-50.80M | $-200.90M | $-91.90M | $-99.20M | $-82.50M | $-153.70M | $-103.90M | $-83.90M | $-64.50M | $-197.40M | $-121.00M | $-89.30M | $-49.50M | $-116.90M | $-38.20M | $-44.50M | $-43.40M |
| Free Cash Flow | $329.30M | $750.50M | $320.30M | $563.80M | $278.50M | $732.00M | $425.90M | $888.70M | $-11.10M | $765.10M | $718.60M | $1.07B | $325.70M | $964.60M | $470.10M | $799.30M | $-80.70M | $486.80M | $335.00M | $247.70M |
Viatris Dividends
Explore Viatris's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
3.87%
Dividend Payout Ratio
-90.63%
Dividend Paid & Capex Coverage Ratio
2.56x
Viatris Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.12 | $0.12 | March 10, 2025 | March 10, 2025 | March 18, 2025 | February 27, 2025 |
| $0.12 | $0.12 | November 22, 2024 | November 22, 2024 | December 13, 2024 | November 04, 2024 |
| $0.12 | $0.12 | August 23, 2024 | August 23, 2024 | September 13, 2024 | August 05, 2024 |
| $0.12 | $0.12 | May 23, 2024 | May 24, 2024 | June 14, 2024 | |
| $0.12 | $0.12 | March 08, 2024 | March 11, 2024 | March 18, 2024 | February 26, 2024 |
| $0.12 | $0.12 | November 22, 2023 | November 24, 2023 | December 15, 2023 | November 07, 2023 |
| $0.12 | $0.12 | August 23, 2023 | August 24, 2023 | September 15, 2023 | August 04, 2023 |
| $0.12 | $0.12 | May 23, 2023 | May 24, 2023 | June 16, 2023 | May 05, 2023 |
| $0.12 | $0.12 | March 08, 2023 | March 09, 2023 | March 17, 2023 | February 24, 2023 |
| $0.12 | $0.12 | November 22, 2022 | November 23, 2022 | December 16, 2022 | November 07, 2022 |
| $0.12 | $0.12 | August 23, 2022 | August 24, 2022 | September 16, 2022 | August 04, 2022 |
| $0.12 | $0.12 | May 23, 2022 | May 24, 2022 | June 16, 2022 | May 05, 2022 |
| $0.12 | $0.12 | February 23, 2022 | February 24, 2022 | March 16, 2022 | January 06, 2022 |
| $0.11 | $0.11 | November 22, 2021 | November 23, 2021 | December 16, 2021 | November 08, 2021 |
| $0.11 | $0.11 | August 23, 2021 | August 24, 2021 | September 16, 2021 | August 09, 2021 |
| $0.11 | $0.11 | May 21, 2021 | May 24, 2021 | June 16, 2021 | May 10, 2021 |
| $0.06 | $0.06 | June 27, 2007 | June 29, 2007 | July 16, 2007 | June 18, 2007 |
| $0.06 | $0.06 | March 28, 2007 | March 30, 2007 | April 16, 2007 | March 15, 2007 |
| $0.06 | $0.06 | December 27, 2006 | December 29, 2006 | January 16, 2007 | December 19, 2006 |
| $0.06 | $0.06 | September 27, 2006 | September 29, 2006 | October 16, 2006 | September 19, 2006 |
Viatris News
Read the latest news about Viatris, including recent articles, headlines, and updates.
Viatris Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - VTRS
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or the "Company") (NASDAQ:VTRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Viatris Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Viatris Inc. (VTRS)
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
VTRS Investor News: Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
NEW YORK , March 24, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ: VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public. So What: If you purchased Viatris securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Viatris Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - VTRS
NEW YORK, NY / ACCESS Newswire / March 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Viatris Inc. Announcement: If You Have Suffered Losses in Viatris Inc. (NASDAQ: VTRS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, March 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ: VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public.
ATTENTION VTRS SHAREHOLDERS: Investors who lost money on Viatris Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESS Newswire / March 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Viatris Inc. Being Investigated on Behalf of Viatris Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESS Newswire / March 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
NEW YORK, NY / ACCESS Newswire / March 22, 2025 / Rosen Law Firm PA WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ:VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Viatris securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Shareholders That Lost Money on Viatris Inc.(VTRS) Should Contact Levi & Korsinsky about Securities Fraud Investigation - VTRS
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility – Hagens Berman
SAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- On February 27, 2025, investors saw the price of their shares of Viatris Inc. (NASDAQ: VTRS) tumble over 15% after the company disclosed an anticipated adverse 2025 monetary impact from the U.S. FDA's recent December 2024 determination concerning the company's oral dose manufacturing facility in Indore, India.
Viatris Inc. (VTRS) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc.(NASDAQ:VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Viatris securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Viatris Inc. (VTRS) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Did Viatris Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - VTRS
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ:VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Viatris securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Lost Money on Viatris Inc. (VTRS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
An Investigation Has Commenced on Behalf of Viatris Inc. Shareholders. Contact Levi & Korsinsky to Discuss your VTRS Losses
NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
VTRS Investigation: Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
NEW YORK , March 18, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ: VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public. So What: If you purchased Viatris securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
An Investigation Has Commenced on Behalf of Viatris Inc. Shareholders. Contact Levi & Korsinsky to Discuss your VTRS Losses.
NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
VTRS ACTIVE INVESTIGATION: Contact Levi & Korsinsky If you Lost Money on your Viatris Inc. Investment
NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for VTRS.